Details of the Drug

General Information of Drug (ID: DM0T2QV)

Drug Name
Sitimagene ceradenovec
Synonyms Cerepro; EG-009; HSV thymidine kinase gene therapy, Ark
Indication
Disease Entry ICD 11 Status REF
Brain cancer 2A00 Discontinued in Phase 3 [1]
Affected Organisms
Humans and other mammals
ATC Code
L01XL01: Sitimagene ceradenovec
L01XL: Antineoplastic cell and gene therapy
L01X: OTHER ANTINEOPLASTIC AGENTS
L01: ANTINEOPLASTIC AGENTS
L: ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS
Cross-matching ID
DrugBank ID
DB04907
TTD ID
D0W8RX

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Thymidine kinase 1 (TK1) TTP3QRF KITH_HUMAN Modulator [2]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Brain cancer
ICD Disease Classification 2A00
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Thymidine kinase 1 (TK1) DTT TK1 1.14E-03 0.26 0.75
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

References

1 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015264)
2 Sitimagene ceradenovec: a gene-based drug for the treatment of operable high-grade glioma. Future Oncol. 2010 Nov;6(11):1691-710.